Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Sodium lauryl sulfate 0.1%, Sodium lauryl sulfate 0.2%, lauryl 0.2%
lauryl 0.1% · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Ibuprofen 5% topical gel | EXPERIMENTAL | - |
| Topical gel vehicle | EXPERIMENTAL | - |
| Sodium lauryl sulfate 0.2% | ACTIVE_COMPARATOR | - |
| Sodium chloride solution 0.9% (saline) | SHAM_COMPARATOR | - |
| Sodium lauryl sulfate 0.1% | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Ibuprofen 5% topical gel | DRUG | 0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions |
| Topical gel vehicle | DRUG | 0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions |
| Sodium lauryl sulfate 0.2% | DRUG | 0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions |
| Sodium chloride solution 0.9% (saline) | DRUG | 0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions |
| Sodium lauryl sulfate 0.1% | DRUG | 0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application |
Inclusion Criteria: Healthy male and/or female subjects (to be confirmed by medical history) 18 years of age or older, female subjects of childbearing potential and males who are using an acceptable form of birth control, subjects who are free of any systemic or dermatologic disorder Exclusion Cri...
Lauryl 0.1% is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE) for pain. It is in Phase 1 clinical development. It is also known as sodium lauryl sulfate 0.1%, sodium lauryl sulfate 0.2%, and lauryl 0.2%.
Lauryl 0.1% targets the sphingosine-1-phosphate receptors S1PR1, S1PR2, S1PR3, S1PR4, and S1PR5. It is classified as a binding agent. This receptor binding activity is the basis of its mechanism of action in pain.
Lauryl 0.1% is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the sponsor responsible for the clinical development of this investigational pain therapy.
Lauryl 0.1% is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. Two Phase 1 trials have been completed, and there are currently no active trials.
Lauryl 0.1% has been studied in two completed Phase 1 trials: NCT01787448, titled RIPT of Ibuprofen Topical Gel, which enrolled 234 participants, and NCT01771822, titled Ibuprofen 5% Topical Gel CIPT, which enrolled 50 participants. Both were conducted in the United States.
Yes. Lauryl 0.1% is also known as sodium lauryl sulfate 0.1%. Other alternative names include sodium lauryl sulfate 0.2% and lauryl 0.2%. These names refer to the same investigational compound being developed by Pfizer for pain.